Discover the latest advancements in selecting cord blood units for hematopoietic stem cell transplantation, a critical step in treating various blood disorders, as discussed in the recent SFGM-TC workshop update.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
[Update for cord blood unit selection in hematopoietic stem cell transplantation (workshop SFGM-TC)].
Dubois et al., Bull Cancer 2024
<!– DOI: 10.1016/j.bulcan.2024.01.009 //–>
https://doi.org/10.1016/j.bulcan.2024.01.009
The recent update on recommendations for allogeneic hematopoietic stem cell transplants (HSC) from cord blood units reflects significant changes in practice and advances in scientific understanding. Previously, HLA compatibility was determined at low resolution for HLA-A and B loci and high resolution for HLA-DRB1. The new guidelines advocate for high-resolution compatibility across all considered loci, including HLA-A, B, C, and DRB1, emphasizing the importance of HLA-C locus and establishing compatibility on 8 alleles. Additionally, while the CD34+ dose is crucial for hematopoietic reconstitution, it’s not directly correlated with the total nucleated cells content, prompting a dual consideration of these metrics in selecting cord blood units. The updated recommendations are presented in a flow chart, accounting for the underlying pathology (malignant or non-malignant), cell dose, HLA compatibility, and storage bank criteria. This approach aims to enhance transplant outcomes by refining donor selection based on more precise genetic matching and cell dose considerations.